P1.12B.07 Iruplinalkib in Patients with ALK-Positive Crizotinib-Resistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial

Yulong Shi(Shandong Provincial Hospital), Xi Kang(Qilu University of Technology), Kangsheng Gu(Anhui Medical University), Bangxian Tan(Affiliated Hospital of North Sichuan Medical College), Yuanyuan Zhao(East China University of Science and Technology), Ming Wang(Wannan Medical College), Mingwei Si(Qilu University of Technology), Sophia Meixuan Zhang(Harvard University), Rong Yang(Nanchang University), Can Hu(Anhui Provincial Hospital), Yue Liu(Shandong Provincial Hospital), Yaqin Yu(Jilin University), Huan Li(Tianjin University), Hui Zhang(Hubei Polytechnic University), Chang Liu(Nanjing Normal University), Yang Zhang(Peking University), Jing Chen(Chongqing University), Zhe Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lixin Zhang(Zhejiang Gongshang University), Lirong Wang(Xi'an Jiaotong University), Ying Hu(Peking University), Xiaohong Wang(South China University of Technology), Xiaohui Hao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shiyu Sun(Guizhou Normal University), Jing Zhao(University of Electronic Science and Technology of China), Wenyu Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jin Shan(Army Medical University), Zhenkun Zhang(Anhui Provincial Hospital), X. Hang(Wuxi Fourth People's Hospital), Lei Yang(Jilin University)
Journal of Thoracic Oncology
October 1, 2024
Cited by 0


Related Papers